FCGR3A and neoplasm: Unlike fragments, which often lack the Fc region and therefore do not recruit effector functions, full‐length antibodies can achieve immune‐mediated tumor cell killing through enhanced ADCC, a process depending on antibody interaction with the FcγRIIIA on NK cells.[58] The observation from preclinical studies that enhanced FcγRIIIA binding could lead to decreased tumor uptake and increased liver and lymphoid organ uptake highlights a complex balance in designing radioimmunoconjugate agents based on full‐length antibodies.